Rokit Healthcare (376900.KQ), an AI-powered hyper-personalized organ regeneration platform company, is moving to capture the European market by unveiling clinical follow-up results on regenerative therapy after skin cancer excision at a European wound care conference.
Rokit Healthcare said Thursday that it is participating in the European Wound Management Association (EWMA) 2026 annual conference, held from Wednesday through Friday local time in Bremen, Germany, where it will exhibit its AI organ regeneration platform. On Thursday, the company will present "Autologous Adipose Tissue Regeneration Using AI Bioprinting After Skin Cancer Tissue Excision and One- to Two-Year Long-Term Follow-Up Results."
The company plans to release observational data on patients tracked for one to two years following regenerative therapy for defect areas left after skin cancer excision. Conventional skin cancer regenerative treatment typically involved suturing after tumor excision or grafting skin from other parts of the body. However, this process often left side effects such as scarring, reduced sensation and diminished skin function.
Rokit Healthcare has developed bioprinting technology that uses the patient's own adipose tissue to print and regenerate damaged areas on the spot. The method restores skin without artificial skin grafts or complex surgery. At the conference exhibition booth, the company plans to demonstrate the entire regenerative treatment process, from wound scanning to the creation of customized regenerative patches.
"Follow-up observations of patients who received AI regenerative technology for up to two years showed no cancer recurrence, and effects including recovery of skin function and sensation as well as minimized scarring were confirmed," a Rokit Healthcare official said.
Based on this clinical data, Rokit Healthcare plans to target the European non-melanoma skin cancer (NMSC) treatment market. The company aims to expand cooperation with local European hospitals and medical device firms and broaden multi-center clinical trials. Non-melanoma skin cancer is the most common type of skin cancer, with a lower risk of metastasis than melanoma but a larger patient population. According to one market research firm, the market is valued at approximately $890 million (1.3 trillion won) as of 2025.
